drugset / Trial / NCT02908763
HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients
Phase 4
Unknown
200 enrolled
Third Affiliated Hospital, Sun Yat-Sen University
First Affiliated Hospital of Kunming Medical University · collabFirst People's Hospital of Foshan · collabFirst People's Hospital, Shunde China · collabHuazhong University of Science and Technology · collabHuizhou Municipal Central Hospital · collabNanchang University · collabPeking University · collabShenzhen Third People's Hospital · collabTang-Du Hospital · collabYuebei People's Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
HBsAg Loss/Seroconversion is uncommon in Low replicative chronic HBV infection patients. The purpose of this study is to investigate the ability of peginterferon alpha to achieve HBsAg loss/seroconversion therapy in Low replicative chronic HBV infection patients with Low Level HBsAg.
Timeline
- Start
- 2016-08
- Primary completion
- 2019-09
- Completion
- 2019-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 80 ug | Subcutaneous |